Literature DB >> 17613600

Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort.

R Pelayo1, M Tintoré, A Rovira, J Rio, C Nos, E Grivé, N Téllez, M Comabella, X Montalban.   

Abstract

Clinically isolated syndromes (CIS) classically refer to optic neuritis (ON), brainstem or spinal cord syndromes. Less common first episodes suggestive of central nervous system (CNS) demyelination, such as hemispheric or clinically polyregional syndromes, have been only slightly studied. The aim of this study was to describe these CIS topographies in our cohort of patient with a CIS. We evaluated 320 patients with a CIS, and classified the topographies of the attacks according to clinical symptoms only into CIS of the optic nerve (123), brainstem (78), spinal cord (89), hemispheric (6), polyregional (12) or undetermined (12) topographies. Patients underwent brain MRI within three months of their first attack, and again 12 months later. Conversion to multiple sclerosis (MS), determined either clinically or by magnetic resonance imaging (MRI), was evaluated according to topography. Hemispheric and polyregional syndromes were closer to brainstem or spinal cord syndromes than ON in clinical and MRI conversion terms, although a statistical analysis was not performed because of the small number of patients. There are differences between several studies in the definition, and, therefore, the prevalence of these so-called atypical CIS. Consensus on the denomination and definition of these syndromes must be reached.

Entities:  

Mesh:

Year:  2007        PMID: 17613600     DOI: 10.1177/1352458506074178

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  2 in total

1.  Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS.

Authors:  Jaume Sastre-Garriga; M Tintoré; C Nos; C Tur; J Río; N Téllez; J Castilló; A Horga; H Perkal; M Comabella; A Rovira; X Montalban
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

Review 2.  Monoclonal antibodies in the therapy of multiple sclerosis: an overview.

Authors:  P S Rommer; O Stüve; R Goertsches; E Mix; U K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 6.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.